EUCTR2011-005361-20-GB进行中（未招募）1 期
A Phase II Trial of combination treatment with Vorinostat, Bortezomib and Dexamethasone in participants with Relapsed Multiple Myeloma - MUK four
niversity of Leeds0 个研究点目标入组 68 人开始时间: 2012年12月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Able to give informed consent and willing to follow study protocol and quality of life assessments
- •Aged 18 years or over
- •Participants with relapsed multiple myeloma who have received 1-3 prior lines of treatment and now require further treatment
- •ECOG Performance Status = 2
- •Required laboratory values:
- •-Absolute neutrophil count =1.0 x 10^9/L
- •-Platelet count =75x10^9/L
- •-Haemoglobin > 9 g/dL
- •-Bilirubin =1.5 x upper limit of normal
- •-ALT and / or AST =2.5 x upper limit of normal
- •-Serum creatinine = 2.0 x upper limit of normal
- •-Corrected calcium = 2.8 mmol/L
- •Life expectancy of at least 3 months
- •Female subjects of child-bearing potential must have a negative pregnancy test at baseline and agree to use dual methods of contraception for the duration of the study and must continue to do so for 3 months after the end of treatment. Male subjects must agree to use a barrier method of contraception for the duration of the study if sexually active with a female of child-bearing potential and must continue to do so for 3 months after the end of treatment
- •Patient is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 34
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •Previous anti-tumour therapies, including prior experimental agents or approved anti-tumour small molecules and biologics, within 28 days before the start of protocol treatment. Steroid therapy to stop rapid relapse during this period is permitted, but must be stopped 7 days prior to study drug administration. Bisphosphonates for bone disease and radiotherapy for palliative intent are also permitted.
- •Prior HDAC inhibitor treatment. Participants who have received compounds with HDAC inhibitor like activity, such as valproic acid, as anti-tumour therapy must not be enrolled in this study. (Participants who have received such compounds for other indications e.g. valproic acid for epilepsy, may enrol after a 30 day washout period)
- •Concurrent or previous malignancies (<12 months post end of treatment) at other sites with the exception of appropriately treated localised epithelial skin or cervical cancer. Patients with histories (=12 months) of other tumours may be entered
- •Patients considered to be refractory to prior bortezomib treatment, defined as:
- •-Relapse on OR within 60 days after the last dose of a bortezomib containing regimen
- •-No clinical response (= SD/NC) on a bortezomib containing regimen.
- •Peripheral neuropathy of = grade 2 severity
- •Patients who have received growth factor support or platelet support within 14 days prior to registration
- •Patient has uncontrolled concurrent illness or circumstances that could limit compliance with the study, including, but not limited to the following: acute or chronic graft versus host disease, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within past 6 months, uncontrolled cardiac arrhythmia, renal failure, psychiatric or social conditions that may interfere with patient compliance, or any other condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient at unacceptable risk for adverse outcome if he/she were to participate in the study.
- •Patients with significant cardiovascular disease (e.g. history of congestive heart failure requiring therapy, presence of severe valvular heart disease, presence of an atrial or ventricular arrhythmia requiring treatment, uncontrolled hypertension, a history of QTc abnormalities or with QTC interval > 480 msecs
- •Active symptomatic fungal, bacterial, and/or viral infection including known active HIV or known viral (A, B, or C) hepatitis.
- •Pregnant or breast feeding females
- •Unable to take corticosteroid therapy at study entry
- •Patient has known hypersensitivity to any components of bortezomib, (such as boron, mannitol), or vorinostat.
- •Patient has known CNS metastases and/or carcinomatous meningitis.
- •Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the Investigator, interfere with the absorption or swallowing of the study drug(s)
研究者
相似试验
尚未招募
不适用
Clinical Study on Vatari Guggulu Internally and Pippalyadi Taila Enema Therapy in Management of SciaticaCTRI/2017/09/009942ri Dharmasthala Manjunatheshwara College of Ayurveda and HospitalHassan
招募中
2 期
Phase II study of combination treatment of nivolumab and TM5614 for non-small cell lung cancer (TM-Uprise Study)non-small cell lung cancerJPRN-jRCT2061230039Hattori Noboru39
尚未招募
不适用
To compare the effect of Varmam therapy and vasavennai oil for shoulder joint degeneratioCTRI/2019/08/020731Dr Vrindha KV
招募中
2 期
A Phase 2 Trial of Multimodal Treatment based on VDC-IE with Interval Compressed Schedule by using G-CSF for Patients with Non-metastatic Ewing Sarcoma Family Tumoron-metastatic Ewing Sarcoma Family TumorJPRN-UMIN000020903Japan Ewing Sarcoma Study Group66
招募中
2 期
JESS14Ewing sarcoma family tumorC04.557.450.565.575.650.800Ewing sarcomaJPRN-jRCTs021180022Sano Hideki66